News

Hosted again in Barcelona, Spain, the Immunoskin conference ran from 26-27 October and brought together leading experts in dermatological conditions and treatments.

Topics covered included the latest breakthroughs in biological therapies and discussions on personalised treatment options available for inflammatory skin conditions, as well as clinical case study presentation and expert debates. One of the main takeaways from the conference was a demonstration of the role that IL-13 – a cytokine secreted by a variety of cells including natural killer T-cells – can have in the treatment for atopic dermatitis. The conference was chaired by Dr Diamant Thaçi, director of the Institute and Comprehensive Center for Inflammation Medicine in Lübeck, Germany, and included attendees from both healthcare and pharma organisations.

Volker Koscielny MD, chief medical officer at Almirall, stated, “Bringing together clinicians and international thought leaders in dermatology during Almiral's ImmunoSkin conference allows for a deep exchange around innovation and areas of unmet need. These meetings have an important place to nurture international collaborations and bear testimony to Almirall’s commitment to medical dermatology”.

The conference was organised by Almirall, a global pharma with an expertise in medical dermatology. Almirall has been a major player in the medical dermatology space for over 50 years, having developed and brought to market several leading therapeutics for skin conditions including aclidinium bromide, clebopride and ebastine.

Speaking about the conference, Dr Diamant Thaçi, chair of the event, remarked, “ImmunoSkin serves as an essential platform for advancing our understanding of autoimmune skin diseases. By bringing together leading experts in a specialised conference dedicated to inflammatory skin conditions, we foster collaboration and share groundbreaking insights that will ultimately enhance patient care.”